Abstract: Disclosed is a family of corroles for its use in the treatment of an infection by human herpesvirus, especially in the treatment of an infection by human cytomegalovirus.
Type:
Grant
Filed:
November 27, 2018
Date of Patent:
July 26, 2022
Assignee:
UNIVERSITE DE BOURGOGNE
Inventors:
Claude Gros, Franck Gallardo, Nicolas Desbois
Abstract: The present invention is directed to pesticidal mixtures comprising sabadilla alkaloids and pyrethrum esters and methods of controlling pests including insects and mites by application of pesticidal mixtures comprising sabadilla alkaloids and pyrethrum esters.
Abstract: The present invention relates to a compound of a novel antiviral nucleoside reverse transcriptase inhibitor, a pharmaceutical composition containing the compound, and preparation and application of the compound. Specifically, disclosed in the present invention are a fused pyrimidine compound as represented by formula (I) and a pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt, stereoisomer, solvate, hydrate, crystal form, prodrug or isotopic derivative of the compound. The compound of the present invention can be used for treatment and/or prevention of infectious diseases caused by viruses, such as human immunodeficiency virus (HIV), hepatitis B virus (HBV).
Abstract: Methods and compositions are provided for inhibiting or treating a viral infection in a subject using cell-impermeable inhibitors of Akt, scramblase and/or a phosphatidylserine.
Type:
Grant
Filed:
November 27, 2018
Date of Patent:
July 12, 2022
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE
Inventors:
Betsy C. Herold, Steven C. Almo, Natalia Cheshenko, Jeffrey Bryan Bonanno
Abstract: The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and the RSV inhibiting Compound B, i.e. (1S,2S)-2-[4-[7-cyclopropyl-5-[(1R)-1-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]pyrazolo[1,5-a]pyrimidin-2-yl]-3-fluoro-phenyl]cyclopropanecarboxylic acid for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and Compound B, a pharmaceutical product comprising Compound A and Compound B, the use of the combination of Compound A and Compound B—or the pharmaceutical product comprising Compound A and Compound B—for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and Compound B in an effective amount to said subject.
Type:
Grant
Filed:
December 4, 2018
Date of Patent:
June 28, 2022
Assignee:
Janssen Sciences Ireland Unlimited Company
Inventors:
Nina Ysebaert, Nele Isa E. Goeyvaerts, Dirk André Emmy Roymans, Anil Koul
Abstract: Methods are provided for treating HIV and cancer in a subject in need thereof by administering to the subject therapeutically effective amounts of an mTOR inhibitor. Other methods are provided for treating subjects infected with HIV by administering to the subject therapeutically effective amounts of the mTOR inhibitor INK128, GSK2126458, AZD2014 or Torin-2.
Type:
Grant
Filed:
September 24, 2019
Date of Patent:
June 21, 2022
Assignee:
UNIVERSITY OF MARYLAND, BALTIMORE
Inventors:
Robert R. Redfield, Alonso Heredia, Charles Davis, Ronald Gartenhaus, Edward A. Sausville
Abstract: A method for providing a therapy to a subject that has been exposed to an Aflatoxin B1 can include administering a compound having a structure of Formula 1 to the subject after exposure to the Aflatoxin B1: wherein: R1, R2, R3, R4, R5 and/or R6 are each individually a chemical moiety and n is 1, 2, 3, 4, or 5. The compound can be Amprenavir or a derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof. The prodrug can be Amprenavir phosphate.
Abstract: Disclosed are methods of treating non-alcoholic steatohepatitis (NASH) and methods of preventing NASH-induced hepatocellular carcinoma (HCC), such methods including administering O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime (BGP15), alone or in combination with a inhibitor of the interleukin-6 receptor transsignaling response, particularly gp130Fc.
Abstract: The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.
Type:
Grant
Filed:
May 14, 2020
Date of Patent:
June 14, 2022
Assignee:
NOVALIQ GMBH
Inventors:
Dieter Scherer, Ralf Grillenberger, Frank Löscher, Hartmut Voss
Abstract: Pharmaceutical formulations comprising ketamine, propofol, and a lipid are provided. Methods of making the formulations and methods of using the formulations to provide sedation, amnesia, analgesia, anxiolysis, and/or stable hemodynamics are also provided.
Type:
Grant
Filed:
April 19, 2018
Date of Patent:
June 14, 2022
Assignees:
Mayo Foundation for Medical Education and Research, Regents of the University of Minnesota
Inventors:
Nathan J. Smischney, Wayne T. Nicholson, Jayanth Panyam
Abstract: Provided herein is a combination of agents for reducing cell viability and/or cell proliferation. The combination comprises an FGFR4 inhibitor and an EGFR inhibitor.
Abstract: The inventive subject matter provides compositions and methods for transiently or permanently treating or managing an injury. Contemplated compositions are polymerizable in situ over short time periods, even in the presence of blood, without undue exothermic heat. Contemplated compositions may further comprise an anesthetic, an antiseptic, an adhesion promoter, and/or a vasoconstrictor.
Abstract: The invention concerns compounds having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. Formula (Ia).
Type:
Grant
Filed:
November 28, 2018
Date of Patent:
May 24, 2022
Assignee:
Janssen Sciences Ireland Unlimited Company
Inventors:
David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Peter Rigaux, Antoine Benjamin Michaut, Guillaume Jean Maurice Mercey
Abstract: Disclosed herein are methods for treating an individual having a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. The method may comprise administering a JAK inhibitor, for example ruxolitinib (JAKAFI®), to an individual in need thereof, such individual generally being an individual having, or suspecting of having, SARS-CoV-2 infection. The individual in need thereof may be an individual having, or suspected of having or at risk for developing SARS-CoV-2 infection-related cytokine storm. The individual in need thereof may further be an individual having, or suspected of having SARS-CoV-2 infection-related pneumonia.
Abstract: A composition for inhibiting sodium leakage channel (NALCN), including as an active ingredient N-benzhydryl quinuclidine (NBQN) or a N-benzhydryl quinuclidine derivative represented by the following Formula 1, wherein in the following Formula 1, R is an unsubstituted or substituted benzyl group
Type:
Grant
Filed:
April 24, 2019
Date of Patent:
April 12, 2022
Assignee:
Research & Business Foundation Sungkyunkwan University
Inventors:
Myoung Kyu Park, Hyun Jin Kim, Suyun Hahn, So Woon Kim
Abstract: Disclosed are a bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders, a method for treating and/or preventing hepatitis virus-related diseases or disorders by using the bisdiazabicyclo compound, and a use of the bisdiazabicyclo compound in the preparation of a drug for treating and/or preventing hepatitis virus-related diseases or disorders, and/or eliminating or mitigating hepatitis virus-related diseases or disorders.
Type:
Grant
Filed:
November 20, 2018
Date of Patent:
April 12, 2022
Assignees:
JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC., HEALTHQUEST PHARMA INC.
Inventors:
Yifan Zhai, Xiaoyong Zhang, Jinlin Hou, Dajun Yang
Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.
Type:
Grant
Filed:
April 13, 2020
Date of Patent:
March 29, 2022
Assignee:
Oncternal Therapeutics, Inc.
Inventors:
Brian Lannutti, Katayoun Jessen, James Bradley Breitmeyer
Abstract: The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomers, to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments.
Abstract: The invention provides pharmaceutical compositions and methods of use thereof for treating Prader-Willi syndrome. More specifically, the invention provides pharmaceutical compositions that when administered inhibit the G9a driven methylation of histone H3 lysine 9.
Type:
Grant
Filed:
May 17, 2017
Date of Patent:
March 22, 2022
Assignees:
Duke University, The University of North Carolina at Chapel Hill
Inventors:
Yong-hui Jiang, Yuna Kim, Hyeong-min Lee, Jian Jin, Bryan L. Roth